<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
    <link rel="stylesheet" href="../css/uswds.min.css">
    <link rel="stylesheet" href="../css/style.css">
    <link rel="stylesheet" href="css/uswds.min.css">
    <link rel="stylesheet" href="css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR310.html">Part 310
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  310.306  Notification of a permanent discontinuance or an use without approved new drug applications.
                            </h3>
                            <p class="depth1"><em>(a)</em> Applicability. Marketed prescription drug products that are not the subject of an approved new drug or abbreviated new drug application are subject to this section.</p><p class="depth1"><em>(b)</em> Notification of a permanent discontinuance or an interruption in manufacturing. The manufacturer of each product subject to this section must make the notifications required under Sec.  314.81(b)(3)(iii) of this chapter and otherwise comply with Sec.  314.81(b)(3)(iii) of this chapter. If the manufacturer of a product subject to this section fails to provide notification as required under Sec.  314.81(b)(3)(iii), FDA will send a letter to the manufacturer and otherwise follow the procedures set forth under Sec.  314.81(b)(3)(iii)(e).</p><p class="depth1"><em>(c)</em> Drug shortages list. FDA will include on the drug shortages list required by Sec.  314.81(b)(3)(iii)(d) drug products that are subject to this section that it determines to be in shortage. For such drug products, FDA will provide the names of each manufacturer rather than the names of each applicant. With respect to information collected under this paragraph, FDA will observe the confidentiality and disclosure provisions set forth in Sec.  314.81(b)(3)(iii)(d)(2).
[80 FR 38938, July 8, 2015]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>. Code available <a href="#">on Github.</a></h5>
      </div>
    </div>
  </footer>
  </body>
</html>
